Risk Evaluation and Mitigation Strategies (REMS) and Generic Drugs

Research ReportCRS In FocusVersion 2

IF10494

Risk Evaluation and Mitigation Strategies (REMS) and Generic Drugs

Published Oct 31, 2016Updated Jun 20, 2025

Full report

What this is

The Congressional Research Service is a nonpartisan policy and legal analysis arm of the Library of Congress. CRS reports are written for members of Congress and their staff, not the public — but they’re made available openly through Congress.gov.

Read the PDF on Congress.gov

HR 2841114th Congress
FAST Generics Act of 2015
Jun 19, 2015 · Referred to the Subcommittee on Health.
S 3056114th Congress
CREATES Act of 2016
Jun 21, 2016 · Committee on the Judiciary Subcommittee on Antitrust, Competition Policy and Consumer Rights. Hearings held.

Risk Evaluation and Mitigation Strategies (REMS) and Generic Drugs

Legislation this report covers